特别提示:包括突变型EGFR抑制剂(Mutated EGFR-IN-1)在内,本公司的所有产品仅可用于科研实验,严禁用于临床医疗及其他非科研用途! 产品名称:突变型EGFR抑制剂(Mutated EGFR-IN-1) 英文名称:Mutated EGFR-IN-1 产品货
中文名称:突变型EGFR抑制剂(Mutated EGFR-IN-1) 英文名称:Mutated EGFR-IN-1 产品规格:1mL(10mM)|2mg|5mg|10mg|50mg|100mg Mutated EGFR-IN-1是突变型EGFR(L858R EGFR,Exonl9缺失活化突变和T790M抗性突变)抑制剂的中间体。 注:本品仅可用于科研实验,严禁用于临床医疗及其他用途!
EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects. Cancer Treat Rev. 2012;38(5):416–30.Soria JC, Mok TS, Cappuzzo F, Janne PA. EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects. Cancer Treat Rev . ...
中文名:Mutated EGFR-IN-3,英文名:Mutated EGFR-IN-3,CAS:2375107-27-8,化学式:C31H29FN4O2,分子量:508.59,MSDS.
Mutated EGFR-IN-1产品规格:1mL(10mM)|2mg|5mg|10mg|50mg|100mg发货周期:1～3天产品价格:询价本产品仅可用于科研实验,严禁用于其他非科研用途!Mutated EGFR-IN-1是突变型EGFR(L858R EGFR,Exonl9缺失活化突变和T790M抗性突变)抑制剂的中间体。注:本品仅可用于科研实验,严禁用于临床医疗及其他用途!CAS号:1421372...
EGFR-mutated lunge cancer in a general Norwegian populationEGFR-mutated lunge cancer in a general Norwegian population | European Respiratory SocietyLilach KleinbergPeter JebsenMarius LundIversenÅslaug HellandLars Fjellbirkeland
产品名称:突变型EGFR抑制剂(Mutated EGFR-IN-1) 英文名称:Mutated EGFR-IN-1 产品货号:M02094 产品规格:1mL(10mM)|2mg|5mg|10mg|50mg|100mg Mutated EGFR-IN-1是突变型EGFR(L858R EGFR,Exonl9缺失活化突变和T790M抗性突变)抑制剂的中间体。 注:本品仅可用于科研实验,严禁用于临床医疗及其他用途! CAS号:142...
strategies for EGFR-mutated NSCLC patients suffering osimertinib resistance for the sake of the improvement of survival and further achievement of precise medicine. Introduction Lung carcinoma constitutes the major cause of cancer-related mortality and has the second greatest prevalence worldwide, according...
Ticiana Leal, MD, gives a comprehensive overview of treatment options for patients with EGFR-mutated NSCLC who progress on osimertinib therapy. EP: 1.Current Treatment Landscape for EGFR-Mutated NSCLC EP: 2.Treatment Options for EGFR-Mutated NSCLC Following Progression Now Viewing EP: 3.EGFR-...
Osimertinib is a third-generation EGFR-TKI, specifically designed to inhibit EGFR sensitizing and T790M acquired mutations, minimizing exposure in EGFR-wildtype tissues. Areas covered: Osimertinib use in EGFR-mutated NSCLC patients is described, focusing on safety and tolerability from studies supporting...